Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O60602

UPID:
TLR5_HUMAN

ALTERNATIVE NAMES:
Toll/interleukin-1 receptor-like protein 3

ALTERNATIVE UPACC:
O60602; B1AZ05; B3Y633; B9VJ63; D1CS80; D3DTB8; O15456; Q32MI2; Q32MI3

BACKGROUND:
The Toll-like receptor 5 (TLR5), alternatively named Toll/interleukin-1 receptor-like protein 3, is integral to innate immunity, acting as a surface receptor that identifies and responds to microbial patterns. Its ability to detect bacterial flagellins and initiate signaling pathways for NF-kappa-B activation and cytokine production highlights its role in inflammatory responses and maintaining the balance of gut microbiota.

THERAPEUTIC SIGNIFICANCE:
TLR5's involvement in systemic lupus erythematosus 1, characterized by autoimmune dysregulation, underscores its potential as a target for therapeutic intervention. Exploring Toll-like receptor 5's functions could lead to innovative treatments for autoimmune conditions, offering hope for improved disease management and patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.